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Introduction {#acn3323-sec-0001}
============

Mutations in *OPA1* were first described in pedigrees with autosomal‐dominant optic atrophy (DOA), which is the most common form of inherited optic nerve blindness in the population.[1](#acn3323-bib-0001){ref-type="ref"}, [2](#acn3323-bib-0002){ref-type="ref"} The visual loss in DOA develops in early childhood and it has a relatively indolent course with 10--20% of *OPA1* mutation carriers remaining visually asymptomatic.[3](#acn3323-bib-0003){ref-type="ref"} Nonpenetrance is also well described, which contributes to the lack of a clear‐cut family history in some affected probands.

*OPA1* encodes for an inner mitochondrial membrane protein that regulates a host of important functions, including the balance between mitochondrial fusion and fission, the stability of the mitochondrial respiratory chain complexes, and the controlled release of proapoptotic cytochrome *c* molecules sequestered within the mitochondrial cristae.[4](#acn3323-bib-0004){ref-type="ref"} DOA is therefore a mitochondrially determined optic neuropathy characterized by the preferential loss of retinal ganglion cells within the inner retina, similar to Leber hereditary optic neuropathy (LHON).

In 1992, Anita Harding and colleagues described eight female patients with the m.11778A\>G mitochondrial DNA (mtDNA) mutation who developed features of both LHON and multiple sclerosis (MS).[5](#acn3323-bib-0005){ref-type="ref"} Subsequent reports of MS occurring in association with all three primary LHON mutations (m.3460A\>G, m.11778A\>G, and m.14484T\>C), raised the distinct possibility of a mechanistic link between these two disorders,[6](#acn3323-bib-0006){ref-type="ref"}, [7](#acn3323-bib-0007){ref-type="ref"}, [8](#acn3323-bib-0008){ref-type="ref"}, [9](#acn3323-bib-0009){ref-type="ref"} supported by mounting evidence of mitochondrial dysfunction in both acute and chronic MS lesions.[10](#acn3323-bib-0010){ref-type="ref"}, [11](#acn3323-bib-0011){ref-type="ref"}, [12](#acn3323-bib-0012){ref-type="ref"} Unlike classical demyelinating optic neuritis, visual loss in LHON‐MS cases (also known as Harding disease) is frequently bilateral at onset and the prognosis is poor with over half of all patients being registered legally blind.[13](#acn3323-bib-0013){ref-type="ref"} However, unlike the well‐recognized link between LHON mtDNA mutations and demyelination, the link between *OPA1* mutations and MS is not well established. To date, an MS‐like illness has only been described in one patient with an *OPA1* mutation,[14](#acn3323-bib-0014){ref-type="ref"} although another patient had coincidental MRI findings consistent with MS,[15](#acn3323-bib-0015){ref-type="ref"} and several case series have described abnormal white matter high signal changes in *OPA1* mutation carriers.[16](#acn3323-bib-0016){ref-type="ref"}, [17](#acn3323-bib-0017){ref-type="ref"}, [18](#acn3323-bib-0018){ref-type="ref"} In this report, we describe three additional unrelated white Caucasian patients who presented to our tertiary neuro‐ophthalmological center with a clinically definite spinal cord MS phenotype, and who were eventually found to harbor pathogenic *OPA1* mutations.

Subjects {#acn3323-sec-0002}
========

Patient A {#acn3323-sec-0003}
---------

A 60‐year‐old woman presented with a 4‐year history of worsening gait and sensory disturbance that was accompanied by urinary urgency and nocturia. She had noticed a slow deterioration in her vision from the age of 50 years, but she was still able to drive. Her mother was registered blind in her later years and she also suffered from Parkinson disease with dementia. The patient had two unaffected sisters. On examination, she had a spastic gait. Power in the lower limbs was normal, but there was increased tone and sustained ankle clonus. Reflexes were brisk and plantar responses were flexor. The patient had a mild reduction in visual acuity and dyschromatopsia, but there was no detectable visual field defect and pupillary light reflexes were preserved (Table [1](#acn3323-tbl-0001){ref-type="table-wrap"}). Optic disc pallor was noted on dilated fundus examination (Fig. [1](#acn3323-fig-0001){ref-type="fig"}). MRI of the brain and spinal cord revealed multiple foci of high T2 signal that were in keeping with demyelination (Fig. [2](#acn3323-fig-0002){ref-type="fig"}A). Oligoclonal bands were detected in the patient\'s cerebrospinal fluid (CSF). Routine hematological, biochemical, and immunological blood tests were normal, including folate and vitamin B12. Anti‐aquaporin 4 antibodies were not present in the patient\'s serum. Genetic testing for the three primary mtDNA LHON mutations was negative. The family history and atypical presentation led us to request *OPA1* genetic screening, which identified a novel heterozygous splice site mutation, c.2356‐1G\>T. No clinical improvement was observed after an empirical 5‐day course of intravenous methylprednisolone. Although the patient\'s vision has remained stable, her spastic paraparesis has progressed rapidly over the subsequent 3 years of follow‐up (EDSS 6.0).

###### 

Clinical and molecular characteristics of the three patients with *OPA1* mutations and an MS‐like disorder

  Subject     Age   Sex   *OPA1* mutation   BCVA (Snellen)   Ishihara plates (/15)   Humphrey^TM^ fields (MD)   Average RNFL thickness (*μ*m)[a](#acn3323-note-0002){ref-type="fn"}                                                                                                
  ----------- ----- ----- ----------------- ---------------- ----------------------- -------------------------- --------------------------------------------------------------------- ------------------------------------------- ------------------------------------------- ---- ----
  Patient A   60    F     c.2356‐1G\>T      20/30            20/30                   3                          3                                                                     −0.74                                       −0.87                                       63   62
  Patient B   56    M     c.870+5G\>A       CF               CF                      0                          0                                                                     N/A[b](#acn3323-note-0003){ref-type="fn"}   N/A[b](#acn3323-note-0003){ref-type="fn"}   64   65
  Patient C   39    F     c.870+5G\>A       20/60            20/60                   1                          1                                                                     −1.22                                       −3.14                                       65   64

Average peripapillary retinal nerve fiber layer thickness was measured using the high‐resolution spectral‐domain Cirrus^TM^ platform (Carl Zeiss Meditec, Dublin, CA).

Patient B was unable to perform Humphrey^TM^ visual field perimetry. Goldmann fields showed bilateral dense central scotomas.

BCVA, best‐corrected visual acuity; CF, counting fingers; LE, left eye; MD, mean deviation (dB); RE, right eye; RNFL, retinal nerve fiber layer.
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![Optic discs appearance and optical coherence tomography (OCT) findings for Patient A. (A) Bilateral optic atrophy (RE, right eye; LE, left eye); (B) OCT measurements were obtained with the high‐resolution spectral‐domain Cirrus^TM^ platform (Carl Zeiss Meditec, Dublin, CA). The average peripapillary retinal nerve fiber layer thickness (RNFL) was 63 *μ*m in the right eye (OD) and 62 *μ*m in the left eye (OS). The analysis software automatically selects the appropriate normative range for the patient and the peripapillary RNFL measurements (dark traces) are represented within color‐coded distribution centiles (bottom panel): (1) red \< 1%, (2) yellow 1--5%, and (3) green 5--95%.](ACN3-3-723-g001){#acn3323-fig-0001}

![Brain and spinal cord MRI abnormalities in three patients with a multiple sclerosis‐like disorder and *OPA1* mutations. Multiple foci of T2 hyperintensity were observed in the periventricular and pericallosal white matter regions. Discreet areas of signal abnormalities were also present in the cervical spinal cord, none of which were longitudinally extensive. Taken together, these neuroradiological findings met the MRI diagnostic criteria for multiple sclerosis. Panel A is patient A, panel B is patient B, and panel C is patient C. Upper panel A = axial T2‐weighted imaging, lower panel A = sagittal T2‐weighted imaging. Upper panel B = axial T1‐weighted imaging, lower panel B = sagittal T2‐weighted imaging. Upper panel C = axial T2‐weighted imaging, lower panel C = sagittal T2‐weighted imaging.](ACN3-3-723-g002){#acn3323-fig-0002}

Patient B {#acn3323-sec-0004}
---------

A 56‐year‐old man was referred with an 8‐year history of progressive walking difficulties with stiffness and weakness in his lower limbs, increasing balance difficulties and paraesthesiae in both hands. His visual difficulties became apparent at the age of 7 years and he has been registered legally blind (Table [1](#acn3323-tbl-0001){ref-type="table-wrap"}). Both optic discs were globally pale and optical coherence tomography (OCT) imaging showed significant thinning of the retinal nerve fiber layer (Fig. S1). The patient had marked asymmetric spastic paraparesis, with the left lower limb being more severely affected than the right. Reflexes were exaggerated at the knees and hypoactive at the ankles. He had reduced sensation to pinprick in a glove and stocking distribution, and vibration sense was absent distally in all four limbs. Neuroimaging was highly suggestive of inflammatory demyelination (Fig. S2B). The patient did not have a lumbar puncture. A comprehensive blood panel was normal and anti‐aquaporin 4 antibodies were not detected. *OPA1* genetic testing revealed a previously reported pathogenic heterozygous splice site mutation, c.870+5G\>A. No clinical response was obtained after a three‐day course of high‐dose intravenous methylprednisolone. His EDSS changed quickly between 2012 and 2015 to 6.0. Interestingly, we subsequently heard that the patient\'s son had been diagnosed with relapsing‐remitting MS and he was receiving disease‐modifying therapy. The son did not harbor the *OPA1* mutation that was identified in his father.

Patient C {#acn3323-sec-0005}
---------

A 39‐year‐old woman first presented in 2002 with paraesthesiae affecting both upper limbs, which lasted for 4 weeks before recovering fully. She represented in 2012 with bilateral numbness and paraesthesiae progressing from her feet to her knees over 1 week. There was accompanying tingling of the hands and positive L\'Hermitte\'s phenomenon. She complained of gradually worsening vision from her early teenage years with no episodes of acute deterioration (Table [1](#acn3323-tbl-0001){ref-type="table-wrap"}). On dilated fundus examination, bilateral optic disc pallor was noted (Fig. S2). Her mother and a maternal uncle were also known to have bilateral optic atrophy, but with no overt neurological deficits. The rest of the patient\'s neurological examination was normal except for reduced vibration sense to the knee (EDSS 2.5). MRI of the brain and spinal cord revealed disseminated white matter lesions consistent with demyelination (Fig. [2](#acn3323-fig-0002){ref-type="fig"}C). CSF was not examined. The patient tested negative for anti‐aquaporin 4 antibodies and the three primary mtDNA LHON mutations (m.3460A\>G, m.11778A\>G, and m.14484T\>C). Given the family history, *OPA1* genetic testing was requested and a heterozygous splice site mutation, c.870+5G\>A, was detected.

Discussion {#acn3323-sec-0006}
==========

The patients described in our case series fulfilled the revised McDonald criteria for a diagnosis of MS, with patients A and B having a primary progressive course, and patient C having a relapsing‐remitting course.[19](#acn3323-bib-0019){ref-type="ref"} All three patients harbored *OPA1* splice site mutations: the previously described c.870+5G\>A variant, and a novel c.2356‐1G\>T variant that affects the canonical splice acceptor site. The *OPA1* c.870+5G\>A mutation causes early‐onset visual loss with a mean age of onset of 10 years old and visual acuities ranging from 20/30 to counting fingers.[3](#acn3323-bib-0003){ref-type="ref"} Two patients with this specific splice site mutation have also been reported where the optic atrophy was complicated by myopathy and peripheral neuropathy, but with no evidence of demyelination.[15](#acn3323-bib-0015){ref-type="ref"} MS affects an estimated 2 in 1000 people in the United Kingdom,[20](#acn3323-bib-0020){ref-type="ref"} and the prevalence of *OPA1*‐positive DOA is 2.9 per 100,000 in the North of England.[21](#acn3323-bib-0021){ref-type="ref"} Approximately, 1 in 18 million of the population or 3--4 people in the UK, will therefore be expected to have both an MS‐like disorder and carry *OPA1* mutations purely by chance. This would explain a case we previously described of a 58‐year‐old woman with an *OPA1* splice site mutation within intron 25 (c.2613+1G\>A) who was unexpectedly found to have MRI findings consistent with demyelination, in the absence of any clear neurological deficits.[15](#acn3323-bib-0015){ref-type="ref"}

Although the three patients we describe here are likely to be a coincidental occurrence, their clinical presentations are not entirely classical for either MS or DOA. As *OPA1* mutation carriers, they had an underlying predisposition to develop an optic neuropathy which progressed slowly over time, and all three patients developed a spinal cord syndrome.[22](#acn3323-bib-0022){ref-type="ref"} Unlike Patient B and Patient C who became aware of progressive visual deterioration in childhood, Patient A had an unusual late presentation in her early fifties with only a mild reduction in central vision (20/30 in both eyes). Although the sensory symptoms resolved in Patient C, suggestive of an acute inflammatory attack, the spinal cord syndromes were relentlessly progressive in the remaining two patients, with a relatively rapid deterioration compared to typical primary progressive multiple sclerosis. This would usually imply ongoing lingering inflammatory disease, but there was no response to high‐dose intravenous methylprednisolone in any of the patients described here. The most likely explanation is an accelerated neurodegenerative mechanism probably mediated by mitochondrial dysfunction. Bilateral visual failure with a spinal cord syndrome suggests NMO, but our patients were aquaporin‐4 antibody negative, making this diagnosis unlikely. Anti‐MOG antibody testing was, however, not performed.

The MS‐DOA overlap syndrome that we describe here seems distinct from the well‐established association between LHON and MS.[5](#acn3323-bib-0005){ref-type="ref"}, [6](#acn3323-bib-0006){ref-type="ref"}, [7](#acn3323-bib-0007){ref-type="ref"}, [8](#acn3323-bib-0008){ref-type="ref"}, [9](#acn3323-bib-0009){ref-type="ref"} With over 60 cases described to date, patients with LHON‐MS typically develop bilateral visual failure that is severe, irreversible, and punctuated by recurrent episodes of acute or subacute deterioration.[13](#acn3323-bib-0013){ref-type="ref"} Although a spinal cord presentation has been described, this is an infrequent occurrence. The majority of patients with LHON‐MS present with sequential visual loss and the predominant neurological phenotype follows a relapsing‐remitting course.[13](#acn3323-bib-0013){ref-type="ref"} These contrasting observations are intriguing because both LHON and DOA are mitochondrial optic neuropathies that primarily target the retinal ganglion cells, resulting in a monosymptomatic ocular disease.[23](#acn3323-bib-0023){ref-type="ref"} However, the spectrum of *OPA1* disease is not limited to the optic nerve and about 20% of mutation carriers can develop additional features, in particular, chronic progressive external ophthalmoplegia, ataxia, and peripheral neuropathy.[15](#acn3323-bib-0015){ref-type="ref"} In comparison, these classical multisystemic features of mitochondrial disease are rare in LHON.[23](#acn3323-bib-0023){ref-type="ref"} Different disease mechanisms are therefore likely to be involved in the development of the more severe neurological "plus" features in *OPA1* and LHON mtDNA mutation carriers. The characteristic vulnerability of the spinal cord seen in the three patients in our case series further highlights the complexity, and the limits of our knowledge, in fully understanding the pathological pathways that modulate mitochondrial neurodegeneration in MS. Clinicians should consider the possibility of an *OPA1*‐related MS‐like disorder in a patient presenting with progressive visual failure and neuroimaging features indicative of a more disseminated inflammatory process. This could lead to the identification of a pathogenic *OPA1* mutation, which will have important implications for the rest of the family and require appropriate genetic counseling. It would also allow the clinician to give a more guarded visual prognosis than would normally be the case in a typical case of demyelinating optic neuritis associated with MS.
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###### 

**Figure S1.** Optic discs appearance and OCT findings for Patient B. (A) Bilateral optic atrophy (RE, right eye; LE, left eye). (B) Optical coherence tomography (OCT) measurements were obtained with the high‐resolution spectral‐domain Cirrus^TM^ platform (Carl Zeiss Meditec, Dublin, CA). The average retinal nerve fiber layer thickness was 64 *μ*m in the right eye (OD) and 65 *μ*m in the left eye (OS).

**Figure S2.** Optic discs appearance and OCT findings for Patient C. (A) Bilateral optic atrophy (RE, right eye; LE, left eye). (B) Optical coherence tomography (OCT) measurements were obtained with the high‐resolution spectral‐domain Cirrus^TM^ platform (Carl Zeiss Meditec, Dublin, CA). The average retinal nerve fiber layer thickness was 65 *μ*m in the right eye (OD) and 64μm in the left eye (OS).

###### 

Click here for additional data file.
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